|
End-of-day quote
Shenzhen S.E.
2026-01-09
|
5-day change
|
1st Jan Change
|
|
31.59 CNY
|
+1.31%
|
 |
+11.12%
|
+11.12%
|
|
Dec. 18 |
Pharmaron Beijing Co., Ltd. Announces Election of Mr. Li Shing Chung Gilbert as Employee Representative Director Effective December 18, 2025
|
CI
| |
25-10-28 |
Pharmaron Acquires Biortus in China
|
BU
| |
25-10-28 |
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
|
CI
| |
25-10-28 |
Pharmaron Beijing Co., Ltd. Announces Resignation of Tsang Kwan Hung Benson as Independent Non-Executive Director
|
CI
| |
25-10-28 |
Pharmaron Beijing Q3 net profit up 42.5% Y/Y
|
RE
| |
25-10-27 |
Pharmaron Beijing Co., Ltd. agreed to acquire 3.08% stake in Wuxi Biortus Biosciences Co. Ltd. from Jiangyin Baiao Management Consulting Enterprise (Limited Partnership), Jiangyin Baisheng Management Consulting Center (Limited Partnership), Jiangyin Baichuang Management Consulting Center (Limited Partnership) and Jiangyin Baiying Management Consulting Center (Limited Partnership), Wu Jiaquan for CNY 27.2 million.
|
CI
| |
25-09-15 |
Pharmaron's Shaoxing Unit Passes US FDA On-Site Inspection
|
MT
| |
25-09-15 |
Pharmaron Beijing announces passing of U.S. FDA on-site inspection- by Pharmaron Shaoxing
|
RE
| |
25-08-25 |
Jefferies Adjusts Pharmaron Beijing's Price Target to HK$28 From HK$22, Keeps at Buy
|
MT
| |
25-08-22 |
Pharmaron Beijing H1 Profit Falls 37%, Revenue Rises 15%
|
MT
| |
25-08-22 |
Nomura Adjusts Pharmaron Beijing's Price Target to 34.62 Yuan From 33.75 Yuan, Keeps at Buy
|
MT
| |
25-08-22 |
Nomura Adjusts Pharmaron Beijing's Price Target to HK$26.63 From HK$25.86, Keeps at Buy
|
MT
| |
25-08-21 |
Pharmaron Beijing's H1 Profit Falls 37%
|
MT
| |
25-08-21 |
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
|
CI
| |
25-08-21 |
Pharmaron Beijing reports HY aggregate revenue of RMB6,441.0 million
|
RE
| |
25-07-16 |
Nomura Adjusts Pharmaron Beijing's Price Target to 33.75 Yuan From 33.31 Yuan, Keeps at Buy
|
MT
| |
25-07-16 |
Nomura Adjusts Pharmaron Beijing's Price Target to HK$25.86 From HK$16.19, Keeps at Buy
|
MT
| |
25-07-16 |
Hong Kong Stocks Fall as Trade Uncertainty Looms, HKMA Steps In to Defend Currency Peg
|
MT
| |
25-07-15 |
Pharmaron Beijing Expects Up to 39% Drop in H1 Profit; Shares Decline 4%
|
MT
| |
25-07-15 |
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2025
|
CI
| |
25-07-15 |
Pharmaron Beijing sees H1 net profit down 36-39% Y/Y
|
RE
| |
25-06-20 |
Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025
|
CI
| |
25-06-04 |
Pharmaron Beijing Co., Ltd.'s Equity Buyback announced on December 16, 2024, has expired.
|
CI
| |
25-06-02 |
Pharmaron Beijing's UK Unit to Invest $30 Million in Biotech Fund
|
MT
| |
25-05-16 |
Pharmaron Beijing's Shareholder To Unload Up To 1.5% Stake In Co
|
RE
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
